IFNB1 and breast cancer: Lan Q [98] et al. demonstrated that high doses of adriamycin and methotrexate chemotherapeutic agents induced immunodormancy in estrogen receptor-negative (ER) breast cancers through the IFN-β/IFNAR/IRF7 pathway.